- Home
- IPW vs BLRX Comparison
IPW vs BLRX Comparison
Compare IPW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- BLRX
- Stock Information
- Founded
- IPW 2018
- BLRX 2003
- Country
- IPW United States
- BLRX Israel
- Employees
- IPW N/A
- BLRX N/A
- Industry
- IPW Catalog/Specialty Distribution
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- BLRX Health Care
- Exchange
- IPW Nasdaq
- BLRX Nasdaq
- Market Cap
- IPW 19.8M
- BLRX 17.2M
- IPO Year
- IPW 2021
- BLRX 2011
- Fundamental
- Price
- IPW $0.58
- BLRX $3.76
- Analyst Decision
- IPW
- BLRX Strong Buy
- Analyst Count
- IPW 0
- BLRX 2
- Target Price
- IPW N/A
- BLRX $19.00
- AVG Volume (30 Days)
- IPW 341.0K
- BLRX 32.7K
- Earning Date
- IPW 11-13-2025
- BLRX 08-14-2025
- Dividend Yield
- IPW N/A
- BLRX N/A
- EPS Growth
- IPW N/A
- BLRX N/A
- EPS
- IPW N/A
- BLRX N/A
- Revenue
- IPW $74,105,251.00
- BLRX $17,251,000.00
- Revenue This Year
- IPW $8.31
- BLRX N/A
- Revenue Next Year
- IPW $77.15
- BLRX N/A
- P/E Ratio
- IPW N/A
- BLRX N/A
- Revenue Growth
- IPW N/A
- BLRX 1.19
- 52 Week Low
- IPW $0.41
- BLRX $2.30
- 52 Week High
- IPW $2.36
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- IPW 54.11
- BLRX 47.80
- Support Level
- IPW $0.49
- BLRX $3.68
- Resistance Level
- IPW $0.63
- BLRX $4.11
- Average True Range (ATR)
- IPW 0.05
- BLRX 0.26
- MACD
- IPW 0.01
- BLRX 0.03
- Stochastic Oscillator
- IPW 70.96
- BLRX 36.17
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.